Video

Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

Author(s):

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

As more therapies become available, more thought will have to be put into determining how best to sequence agents. In the relapsed setting, that will be the most important aspect of treatment, says Nadeem. If 4-drug regimens are adopted into the frontline setting, their impact on subsequent exposure to later lines of therapy and current standards of care, such as stem cell transplantation, will need to be assessed.

Escalation and de-escalation of therapy is another component of individualizing treatment. As such, tools are needed that will alert providers to when a patient who begins intensive therapy can de-escalate their treatment. These questions have never been truly asked before, says Nadeem. Over time, more medications and tools will be developed to individualize therapy for patients; this will be critical as no 2 patients with myeloma are alike, concludes Nadeem.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity